Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Gael Jesus Pino Alva, a 2-year-old treated with gene therapy, with his mother, Giannina Alva. Photo: Peter Barta/St. Jude

Scientists announced that they have "cured," at least for the near-term, the rare genetic disorder that causes a male baby to be born with little or no immune system, or what's commonly known as the "bubble boy disease."

Why it matters: It's estimated that only 40–100 babies are born yearly with this disorder, but almost all of them died within 2 years unless they were diagnosed and placed into sterile environments, like those dramatized in movies and real documentaries. The study, published on Wednesday in the New England Journal of Medicine, says the therapy already has helped a couple of the toddlers enough to play like healthy children and even enter day care.

Background: X-SCID (X-linked severe combined immunodeficiency) is a life-threatening genetic disorder male babies can get if there's a mutation in a gene on the X chromosome called IL2RG.

  • Babies born with SCID have no defense against germs — even the common cold can be deadly.
  • Currently, the most effective treatment is to find a bone marrow match, preferably from a sibling, and transplant stem cells. This works particularly well if done in the first 3 months of a child's life, but it is very difficult to find a match.
  • Because gene therapy is relatively new, scientists consider diseases with mutations in single genes, like SCID, to be prime candidates. However, it's still experimental, so this trial was only done on children without a bone marrow match.
  • Prior therapies had mixed results (they only produced one type of immune cell) or were halted after causing leukemia, likely resulting from the different vector that transports the new gene to the cell.
  • But before this study, the National Institutes of Health tested a treatment using a new lentivirus vector on 5 older SCID patients with promising early results.

What they did: St. Jude Children's Research Hospital, which led the study and co- developed the new lentivirus vector with NIH, used a novel approach to the therapy combining the new vector and a low dose of chemotherapy.

  • The new lentivirus vector was engineered from a de-activated HIV virus and includes insulators to block activation of genes adjacent to the insertion to prevent leukemia.
  • They selected 8 children, ages 2 months to 14 months without donor matches, and collected their bone marrow, inserted the gene in the lab, and froze it while they did quality testing.
  • Before having it reinfused, the infants received 2 days of low-dose busulfan chemo to make space for the new bone marrow cells to grow.

What they found: James Downing, president and CEO of St. Jude, said in a press conference that the trial had "outstanding results" with children "responding to vaccines and able to live normal lives."

  • Most patients were discharged from the hospital within 1 month, and within 3 months, immune cells were present in the blood of all but 1 patient, who required a second dose of gene therapy.
  • Study co-author Ewelina Mamcarz said in a press conference that they were thrilled to see the development of all 3 main types of immune cells: T-cells, B-cells and natural killer cells.
  • 4 infants were able to discontinue intravenous immunoglobulin treatment that give additional antibodies to boost immunity. And 3 of the 4 developed normal antibody responses to normal vaccinations — an indication of robust B-cell function, she said.
  • While acknowledging that it is rare in the scientific community to claim a "cure," Mamcarz says, "They are cured because for the first time we were able to restore all three cells that constitute the immune system."
  • There was no early indication of leukemia up to 2.5 years after the first treatment, she adds. However, the authors said, the children will be closely monitored to see how durable the cure will be.

What they're saying: Rebecca Hatcher Buckley, immunology professor at Duke University School of Medicine who was not part of this study, says the vector in particular is "very promising," particularly as the treatment so far has not produced leukemia.

  • However, she says right now it's not clear they will all have robust B-cell functions and the children will need to be watched for side effects from the chemo, such as possible infertility.
  • "Compared with previously tested gene-therapy strategies for X-SCID, which used other vectors and chemotherapy regimens, the current approach appears safer and more effective," NIH said in a press release.

What's next: The trial is ongoing and St. Jude has signed an exclusive license with Mustang Bio to determine the best strategy to commercialize the immunotherapy for other genetic disorders, possibly including sickle cell disease.

Go deeper

Behind GameStop's latest stock surge

Illustration: Aïda Amer/Axios

Back in focus: The meme stock trade.

By the numbers: GameStop finished up 19%, after a wild day that saw shares spike as much as 80%.

AT&T spins off U.S. video business via deal with TPG

Photo: AaronP/Bauer-Griffin/GC Images

AT&T is spinning off three of its video services, including its satellite TV brand DirecTV, to create a new standalone video company called New DIRECTV.

Details: The company will be jointly owned by AT&T and private-equity giant TPG. AT&T will retain a 70% stake and TPG will own 30% of the firm.

Updated 1 hour ago - Sports

Ex-USA Gymnastics coach dies by suicide after being charged with human trafficking

John Geddert. Photo: AFP via Getty Images

The body of John Geddert was found on Thursday, just hours after the former USA Gymnastics coach was charged with 24 counts of criminal misconduct, according to Michigan Attorney General Dana Nessel.

What they're saying: “My office has been notified that the body of John Geddert was found late this afternoon after taking his own life. This is a tragic end to a tragic story for everyone involved," Nessel said in a statement.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!